Treatment of recurrent and metastatic carcinoma of cervix: a comparison of low dose methotrexate with adriamycin plus methotrexate.
Sixty-six patients with recurrent or metastatic cervical cancer were treated with two different chemotherapy regimens in the last 11 years. Thirty-three patients received weekly low-dose methotrexate (MTX) regimen A and the other 33 patients were treated with a combination of adriamycin and MTX, regimen B. Response rates were 15.2% and 42.4% with regimens A and B respectively (P = 0.014). Symptomatic relief, duration of response and median survival were similar in both groups. General and haematological toxicities were higher including one toxic death with regimen B. Considering the quality of remaining life of the patient low dose MTX is preferred for the treatment of symptomatic recurrent and metastatic cervical cancer.
Sabir
A A
AA
University Department of Radiotherapy, Cookridge Hospital, Leeds.
Khoury
G G
GG
Joslin
C A
CA
Head
C
C
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D012189:Retrospective Studies; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology
D004317:Doxorubicin; D008727:Methotrexate